SIGLEC1 and central nervous system cancer: Meanwhile we explored the role of SIGLEC1 (also known as CD169) and FPR3 in the prognosis and immunotherapy of glioma and thought them would be new biomarkers and targets in diagnoses and treatment of glioma.